The role of dapagliflozin in the management of heart failure: an update on the emerging evidence

M Gupta, S Rao, G Manek, GC Fonarow… - … and clinical risk …, 2021 - Taylor & Francis
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …
被引用次数：22 相关文章

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence.

M Gupta, S Rao, G Manek, GC Fonarow… - … and Clinical Risk …, 2021 - go.gale.com
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

M Gupta, S Rao, G Manek… - … and Clinical Risk …, 2021 - search.proquest.com
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

M Gupta, S Rao, G Manek, GC Fonarow… - … and Clinical Risk …, 2021 - dovepress.com
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence.

M Gupta, S Rao, G Manek, GC Fonarow… - … and Clinical Risk …, 2021 - europepmc.org
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …
[HTML] nih.gov

[HTML][HTML] The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

M Gupta, S Rao, G Manek, GC Fonarow… - … and Clinical Risk …, 2021 - ncbi.nlm.nih.gov
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

M Gupta, S Rao, G Manek… - … and clinical risk …, 2021 - pubmed.ncbi.nlm.nih.gov
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence.

M Gupta, S Rao, G Manek… - … & Clinical Risk …, 2021 - search.ebscohost.com
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence.

M Gupta, S Rao, G Manek, GC Fonarow, RK Ghosh - 2021 - escholarship.org
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

M Gupta, S Rao, G Manek, GC Fonarow… - … and Clinical Risk …, 2021 - dovepress.com
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …